Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by t…
The Affordable Insulin Now Act (H.R. 6255) requires group and individual health plans (including ERISA-covered plans) beginning for plan years on or after January 1, 2026, to cover selected insulin products without applying a deductible and to limit cost-sharing for a 30-day supply to the lesser of $35 or 25 percent of the negotiated price net of price concessions (including PBM concessions).
The bill defines “selected insulin products” as at least one product of each dosage form and insulin type, and it defines insulin by reference to biologics licensed under PHSA section 351.
Plans are not required to apply these cost-sharing limits to out-of-network providers and may impose higher cost-sharing for out-of-network care; cost-sharing paid under the new rules counts toward deductibles and out-of-pocket maximums.
The bill targets a high-profile consumer issue with concrete, administrable rules and an immediate effective date, which increases its political appeal. However, it imposes binding mandates across major statutory regimes that will provoke organized industry opposition and raise questions about cost-shifting, premium effects, and implementation mechanics. Without clear offsets, stakeholder compromise language, or procedural vehicles that lower supermajority barriers, the bill's path to becoming law faces meaningful obstacles—particularly in a chamber requiring broad consensus.
Relative to its intended legislative type, this bill is a clear substantive policy change that establishes specific cost-sharing limits for insulin across major health-law frameworks. The bill is detailed in key operative elements (caps, definitions, cross-statutory amendments, effective date) but omits several administrative and accountability details commonly expected for a nationwide coverage mandate.
Scope and federal mandate: liberals/centrists accept a federal coverage floor to protect consumers; conservatives object to federal intrusion into plan design and employer costs.
Scope and federal mandate: liberals/centrists accept a federal coverage floor to protect consumers; conservatives object to federal intrusion into plan design and employer costs.
A liberal-leaning observer would likely view this bill as a substantial, pragmatic step to reduce out-of-pocket costs for people with diabetes by capping monthly insulin cost-sharing and ensuring those payments count toward deductibles and out-of-pocket maxima.
They would welcome the explicit inclusion of PBM and other price concessions when calculating the 25 percent option, since that attempts to reflect net prices rather than gross list prices.
At the same time, they would note limitations: the bill does not eliminate cost-sharing entirely in all cases, allows plans to select which insulin products to cover, and permits higher cost-sharing for out-of-network care.
A centrist/ moderate observer would generally favor the bill’s goal of reducing insulin cost-sharing for patients while being attentive to trade-offs for employers, insurers, and overall health system costs.
They would see the $35-per-30-day cap coupled with the alternative 25%-of-net negotiated-price rule as a reasonably targeted consumer relief measure, but they would want independent fiscal estimates (CBO) and clarification about administrative implementation and potential premium effects.
The centrist would also note that the bill aligns federal standards across plan types but would want safeguards for small employers and clarity on how negotiated prices and concessions are measured.
A mainstream conservative observer would be sympathetic to the goal of lowering patients’ insulin costs but would be concerned that this bill imposes a federal mandate on private health plans and employers, potentially increasing premiums and administrative complexity.
They would emphasize respect for employer plan design and state-level regulation, and worry about federal overreach into ERISA plans and market distortions that could incentivize price increases or shifting costs.
They would view the out-of-network carve-out as a modest positive but would likely prefer market-based or targeted means-testing approaches rather than a broad, across-the-board federal mandate.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
The bill targets a high-profile consumer issue with concrete, administrable rules and an immediate effective date, which increases its political appeal. However, it imposes binding mandates across major statutory regimes that will provoke organized industry opposition and raise questions about cost-shifting, premium effects, and implementation mechanics. Without clear offsets, stakeholder compromise language, or procedural vehicles that lower supermajority barriers, the bill's path to becoming law faces meaningful obstacles—particularly in a chamber requiring broad consensus.
The bill has not accumulated any surfaced votes yet.
Scope and federal mandate: liberals/centrists accept a federal coverage floor to protect consumers; conservatives object to federal intrusi…
The bill targets a high-profile consumer issue with concrete, administrable rules and an immediate effective date, which increases its poli…
Relative to its intended legislative type, this bill is a clear substantive policy change that establishes specific cost-sharing limits for insulin across major health-law frameworks. The bill is detailed in key operati…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.